# A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

> **NCT04102124** · PHASE2 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Prostate Cancer
- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** SHR3680
- **DRUG:** SHR3162
- **DRUG:** SHR3680(Placebo)
- **DRUG:** SHR3162(Placebo)

## Key facts

- **NCT ID:** NCT04102124
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-08
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The sponsor's R\&D strategy is adjusted.
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102124, "A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04102124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*